MTD Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors

  • STATUS
    Recruiting
  • participants needed
    42
  • sponsor
    Haim Bio Co., Ltd.
Send
Updated on 19 February 2024
See if I qualify

Summary

The objectives of this study are:

Part 1:

  • To assess the MTD, safety and efficacy of each NYH817G and NYH100P in monotherapy in patients with advanced solid tumors who have failed approved standard therapies.
  • To assess the PK properties and the preliminary effectiveness of monotherapy of NYH817G and NYH100P.

Part 2:

  • To assess the MTD, RP2D, safety and efficacy of NYH817G and NYH100P in combination therapy in patients with advanced solid tumors who have failed approved standard therapies
  • To assess the PK properties, the preliminary effectiveness and the changes in metabolism of combination therapy of NYH817G and NYH100P.

Details
Condition Advanced Solid Tumors
Age 19-100 years
Treatment NYH817G, NYH100P, NYH817G and NYH100P
Clinical Study IdentifierNCT04262739
SponsorHaim Bio Co., Ltd.
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

+ years old
Diagnosed with advanced solid tumor histologically/cytologically
Patient without standard therapies or who have failed approved standard therapies
Those with a disease that is measurable and/or evaluable with the appropriate imaging examination according to RECIST v1.1
ECOG performance status 0 to 2
Patients with the suitable marrow, kidney, liver functions, blood coagulation and glycemic control functions
Patients whose Life expectancy is over 12 weeks
Patients who signed the agreement to voluntarily participate in this study

Exclusion Criteria

Patients who have received a major surgery, radiotherapy, chemotherapy, biologic therapy, targeted therapy, cancer immunotherapy or metabolic therapy within specified weeks counting from the initial administration of the IPs
Diagnosed with a malignant tumor other than the relevant disease in the last 5 years from the initial administration of the IPs
Toxicity level has not been recovered to CTCAE Grade 1 or lower
Has uncontrolled metastasis to the CNS
Suspected of having a serious infectious disease, paralysis of intestine, bowel obstruction, interstitial pneumonia or pulmonary fibrosis
Had serious GI bleed or a disease that may affect the absorption of the oral drug in the past 4 weeks
Considered as having a serious heart disease by the investigator or a serious internal disease
Has administered a drug from another study within 4 weeks
Has administered live vaccines within 4 weeks
Has abused substance or alcohol within 12 weeks
Has a serious trauma
Has a history or currently has a type 1 or 2 diabetes
Has a history of lactic acidosis
Has glucose-6-phosphate dehydrogenase deficiency
Has HIV or active or an active hepatitis B or C
Has a history of psychological condition that could threaten observation of this protocol
Has a history of hypersensitive reaction to the main ingredient or component of the IP or biguanide class drugs
Being pregnant or a lactating woman, or (+) pregnancy test
A female subject of a childbearing age who plans to get pregnant or disagrees to use recommended contraceptions
Has not agreed to abstain from alcohol
Considered as unsuitable for the study for other reason by the investigator
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.